Nuvalent Appoints Christy Oliger to Board of Directors
Provided By PR Newswire
Last update: Jun 18, 2025
CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors.
Read more at prnewswire.com
